Publicaciones

  • San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.( 2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-66.
    ABSTRACT CORTESÍA DE PUBMED

  • Mateos, M. V., Hernández, M. T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., ... & San Miguel, J.F. (2013). Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New England Journal of Medicine, 369(5), 438-447.
    ABSTRACT CORTESÍA DE PUBMED

  • Fresquet V, Rieger M, Carolis C, García-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood, 2014 Apr 30. [Epub ahead of print] PMID: 24786774.
    ABSTRACT CORTESÍA DE PUBMED

  • Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting K, Aznar A, Elemento O, Fontan L, Shaknovich R, Fres- quet V, Robles EF, Sagaert X, Melnick A, Martinez-Climent JA. Downregulation of FOXP1 is required during germinal center B-cell function. Blood, 2013 May 23;121(21):4311-20.
    ABSTRACT CORTESÍA DE PUBMED

  • Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD (2014). Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia. SET binding drugs have antagonistic activity. Leukemia. 2014 Apr 30. [Epub ahead of print]. Impact Factor 2010: 10.164. Ranking: 4/65 (HEMATO- LOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Anupriya A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen D, Druker BJ (2014). Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcome drug resistance in myeloid leukemia. Clin Cancer Res 20:2092-103. Impact Factor 2012: 7.837 . Ranking: 12/196 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Pérez C, Pascual M, Martín-Subero JI, Bellosillo B, Segura V, Delabesse E, Álvarez S, Larrayoz MJ, Rifón J, Cigudosa JC, Besses C, Calasanz MJ, Cross NC, Prósper F, Agirre X. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013;98:1414-1420.
    ABSTRACT CORTESÍA DE PUBMED

  • Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, José-Eneriz ES, Mi- randa E, Martín-Subero JI, Garate L, Blanco-Prieto MJ, García de Jalón JA, Rio P, Rifón J, Cigudosa JC, Mar- tinez-Climent JA, Román-Gómez J, Calasanz MJ, Ribera JM, Prósper F. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia. 2012 Jul;26(7):1517-26. doi: 10.1038/leu.2012.31. Epub 2012 Feb 6.
    ABSTRACT CORTESÍA DE PUBMED



"La interacción entre científicos y médicos permite desarrollar proyectos traslacionales de alto impacto que puedan derivar personalizada para leucemias, linfomas y mielomas", Dr. Felipe Prósper, director del programa.

Contactar

Contacto:
Marisol Ripa
Avda. Pío XII, 53
31008 Pamplona
España

(+34) 948 194 700 Ext. 1010
msripa@unav.es